60323-99-1

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C6H5BrN2O3/c1-4-2-5(9(11)12)3-6(7)8(4)10/h2-3H,1H3

Upstream product

• 91668-84-7 2-bromo-6-methylpyridine N-oxide 
• 5315-25-3 2-bromo-6-methylpyridine 

Downstream Products

• 79055-59-7 2-bromo-6-methyl-pyridin-4-ylamine 
• 1417728-94-9 ethyl (6-methyl-4-nitropyridin-2-yl)(phenyl)phosphinate 
• 1417728-96-1 4-bromo-6-methylpyridin-2-yl(phenyl)phosphinic acid 
• 1417728-97-2 ethyl (6-methyl-4-(bromopyridin-2-yl)(phenyl)phosphinate) 
• 1421932-22-0 ethyl (4-[2-(4-methoxyphenyl)ethynyl]-6-methylpyridin-2-yl)(phenyl)phosphinate 
• 1417728-98-3 ethyl (4-bromo-6-methyl-1-oxo-1-pyridin-2-yl)(phenyl)phosphinate 
• 1417729-00-0 (4-bromo-6-[ethoxy(phenyl)phosphoryl]pyridine-2-yl)methyl acetate 
• 1417729-03-3 (6-[ethoxy(phenyl)phosphoryl]-4-[2-(4-methoxyphenyl)ethynyl]pyridine-2-yl)methyl acetate 
• 1417729-11-3 ethyl (6-(hydroxymethyl)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-yl)(phenyl)phosphinate 
• 1417729-32-8 ethyl-[6-(bromomethyl)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-yl](phenyl)phosphinate 
• 1417729-01-1 (6-[ethoxy(phenyl)phosphoryl]-4-[2-(4-(2-[2-(2-methoxyethoxy)ethoxy]ethoxy)phenyl)ethynyl]pyridin-2-yl)methyl acetate 
• 1417729-02-2 (4-(2-[4-(3-([(tert-butoxy)carbonyl]amino)propoxy)phenyl]ethynyl)-6-[ethoxy(phenyl)phosphoryl]pyridin-2-yl)methyl acetate 
• 1417729-09-9 ethyl [6-(hydroxymethyl)-4-[2-(4-(2-[2-(2-methoxyethoxy)ethoxy]ethoxy)phenyl)ethynyl]pyridin-2-yl](phenyl)phosphinate 
• 1417729-15-7 ethyl [6-(bromomethyl)-4-[2-(4-(2-[2-(2-methoxyethoxy)ethoxy]ethoxy)phenyl)ethynyl]pyridin-2-yl](phenyl)phosphinate 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES

The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.

NOVEL COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES

The present invention concerns complexing agents of formula (I) in which a, b, c, chrom1, chrom2, chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lantha

Very bright europium complexes that stain cellular mitochondria

The synthesis, structure and photophysical properties of a series of highly emissive europium complexes is reported. Certain complexes enter mammalian cells by macropinocytosis and stain the mitochondria selectively, allowing observation of the Eu emission in cellulo by time-gated spectral imaging. The Royal Society of Chemistry 2013.

HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR USE IN THE TREATMENT HELMINTH INFECTION

This invention relates to certain heteroaryl compounds for use as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of helminth infections and the treatment of parasitosis caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds.

HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT

This invention relates to certain heteroaryl compounds which may be used as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of parasitic infections such as helminth infections and the treatment of parasitosis caused by such infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists

Optimisation of affinity, chemical stability, metabolic stability and solubility led from a chemically labile HTS hit 1 to mGlu5 receptor antagonists (24-26) with high affinity for the allosteric MPEP binding site, improved microsomal metabolic stability and anxiolytic-like activity in vivo as assessed by the Vogel conflict drinking test.